CCI Okays Acquisition Of 100% Shares In GlaxoSmithKline Asia By Parent Group Entities

New Delhi: Competition Commission of India (CCI) has okayed the acquisition of GlaxoSmithKline Asia Private Limited (GSKAPL) shareholding by GlaxoSmithKline Consumer Healthcare Overseas Limited and GlaxoSmithKline Consumer Healthcare UK Trading Limited.GSKAPL is a client healthcare firm, concerned within the advertising and distribution of oral healthcare merchandise below numerous model names resembling Sensodyne, Parodontax, Polident and over-the-counter medicines merchandise below the model names resembling Crocin and ENO.The proposed mixture entails collective acquisition of 100 per cent shares of the corporate. Prior to the proposed mixture, GSKAPL will purchase the emblems pertaining to "Iodex" and "Ostocalcium" manufacturers in India alongwith the authorized, financial, business and advertising rights of such manufacturers and different related belongings (GSK Consumer Brands) from GlaxoSmithKline Pharmaceuticals Limited, the CCI stated in a press release.GlaxoSmithKline Consumer Healthcare Overseas Limited is a wholly-owned subsidiary of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited ("GSK CH HoldCo"). It is part of the general GlaxoSmithkline (GSK) group and its principal exercise is to behave as an funding holding firm for GSK CH HoldCo and its subsidiaries.GlaxoSmithKline Consumer Healthcare UK Trading Limited is part of the general GSK group and is a wholly-owned subsidiary of GSK CH HoldCo.It is concerned within the distribution and sale of client healthcare merchandise, manufacturing, advertising, offering administration providers to the patron healthcare group and offering analysis and growth providers to different client healthcare firms inside the GSK group.